WO2009149166A3 - Methods and compositions for the diagnosis and treatment of proliferative disorders - Google Patents

Methods and compositions for the diagnosis and treatment of proliferative disorders Download PDF

Info

Publication number
WO2009149166A3
WO2009149166A3 PCT/US2009/046103 US2009046103W WO2009149166A3 WO 2009149166 A3 WO2009149166 A3 WO 2009149166A3 US 2009046103 W US2009046103 W US 2009046103W WO 2009149166 A3 WO2009149166 A3 WO 2009149166A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
expression
treatment
markers
mpnst
Prior art date
Application number
PCT/US2009/046103
Other languages
French (fr)
Other versions
WO2009149166A2 (en
Inventor
Nancy Ratner
Shyra J. Miller
Original Assignee
Children's Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital Medical Center filed Critical Children's Hospital Medical Center
Publication of WO2009149166A2 publication Critical patent/WO2009149166A2/en
Publication of WO2009149166A3 publication Critical patent/WO2009149166A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention identifies expression markers associated with neurofibromatosis 1 (NF1) by examining gene expression in tissue from lesions from neurofibromas, plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNST). The present invention also provides for diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism. The present invention relates to novel, rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that act as a therapeutic agent for the treatment of a proliferative disorder. In another aspect, the present invention provides a method of treating a patient with neurofibromatosis and/or MPNST, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene related to the NF1-Ras pathway.
PCT/US2009/046103 2008-06-03 2009-06-03 Methods and compositions for the diagnosis and treatment of proliferative disorders WO2009149166A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5842808P 2008-06-03 2008-06-03
US61/058,428 2008-06-03

Publications (2)

Publication Number Publication Date
WO2009149166A2 WO2009149166A2 (en) 2009-12-10
WO2009149166A3 true WO2009149166A3 (en) 2010-01-28

Family

ID=41398837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046103 WO2009149166A2 (en) 2008-06-03 2009-06-03 Methods and compositions for the diagnosis and treatment of proliferative disorders

Country Status (1)

Country Link
WO (1) WO2009149166A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
WO2011116209A2 (en) * 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
WO2012015765A2 (en) 2010-07-27 2012-02-02 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CN103045741B (en) * 2012-12-26 2014-07-02 首都医科大学宣武医院 Kit for diagnosing cerebrovascular stenosis and application thereof
CN104372081B (en) * 2014-10-29 2016-08-17 华南农业大学 The LAMP detection primer of one group of Eggs of Silkworm microsporidian and kit
CN110846343B (en) * 2019-11-09 2020-12-01 河南理工大学 Preparation and purification method of recombinant adenovirus expressing Sox4 gene
WO2022087023A1 (en) * 2020-10-19 2022-04-28 Baruch S. Blumberg Institute Methods and kits for diagnosing and treating cancers
KR102706327B1 (en) * 2021-03-24 2024-09-13 재단법인 아산사회복지재단 Composition for Differential Diagnosis of Malignant Peripheral Nerve Sheath Tumor
US20240175872A1 (en) * 2021-03-24 2024-05-30 The Asan Foundation Composition for differential diagnosis of malignant peripheral nerve sheath tumor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091927A1 (en) * 2000-06-27 2004-05-13 Lan Kluwe Method for the determination of data for the preparation of the diagnosis of phakomatosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091927A1 (en) * 2000-06-27 2004-05-13 Lan Kluwe Method for the determination of data for the preparation of the diagnosis of phakomatosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FATHALLAH-SHAYKH ET AL.: "Genomic expression discovery predicts pathways and opposing functions behind phenotypes.", J. BIOL. CHEM., vol. 278, no. 26, 27 June 2003 (2003-06-27), pages 23830 - 23833 *
GUTMANN ET AL.: "Comparative gene expression profile analysis of neurofibromatosis 1- associated and sporadic pilocytic astrocytomas.", CANCER RES., vol. 62, no. 7, 1 April 2002 (2002-04-01), pages 2085 - 2091 *
KIM ET AL.: "Analysis of mammalian septin expression in human malignant brain tumors.", NEOPLASIA, vol. 6, no. 2, March 2004 (2004-03-01), pages 168 - 178 *
LEE ET AL.: "Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells.", NEURON. GLIA. BIOL., vol. 1, no. 2, May 2004 (2004-05-01), pages 135 - 147 *
LEVY ET AL.: "Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1.", CLIN. CANCER RES., vol. 13, no. 2, P.1, 15 January 2007 (2007-01-15), pages 398 - 407 *
RUSSELL ET AL.: "Do septins have a role in cancer?", BR. J. CANCER., vol. 93, no. 5, 5 September 2005 (2005-09-05), pages 499 - 503 *
TANG ET AL.: "Blood gene expression profiling of neurologic diseases: a pilot microarray study.", ARCH. NEUROL., vol. 62, no. 2, February 2005 (2005-02-01), pages 210 - 215 *
TANG ET AL.: "Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1.", BRAIN RES. MOL. BRAIN RES., vol. 132, no. 2, 20 December 2004 (2004-12-20), pages 155 - 167 *

Also Published As

Publication number Publication date
WO2009149166A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2009149166A3 (en) Methods and compositions for the diagnosis and treatment of proliferative disorders
US20220016059A1 (en) Methods for the treatment of bladder cancer
Heist et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
Stubblefield et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study
MX2009002921A (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism.
WO2003082078A3 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
EP3795141A1 (en) Solid solution compositions
MX2009002924A (en) Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders.
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
TW200740452A (en) Therapeutic gastrodia extracts
Delorme et al. Treatment of Neuropathic Pain with 5% Lidocaine‐Medicated Plaster: Five Years of Clinical Experience
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
WO2011066521A3 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
EP2862572B1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
MA30720B1 (en) ANALOGUES OF 2-PHENOXYPYRIMIDINONE
Mischoulon et al. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding
Yildirim et al. Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality
Ilhan et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease
WO2010051196A8 (en) Novel substituted azabenzoxazoles
Mao et al. Characteristics and outcomes of primary central nervous system lymphoma: a retrospective study of 91 cases in a Chinese population
Takei et al. Management of cancer pain due to bone metastasis
BRPI0415215A (en) application of a polyphenol for the treatment of a cancerous or precancerous skin lesion
KR102232198B1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
KR101901001B1 (en) A Pharmaceutical composition comprising PPAR-β inhibitor for enhancing Anti-cancer effect
WO2009089066A3 (en) Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759325

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09759325

Country of ref document: EP

Kind code of ref document: A2